Last updated on September 2018

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Brief description of study

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.

Clinical Study Identifier: NCT03156621

Find a site near you

Start Over

Regeneron Research Site

Cape Town, South Africa
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.